Effect of etofibrate and nicanartine on plasminogen activator inhibitor type-1 production in vitro by cultured vascular cells and on plasma plasminogen activator inhibitor type-1 activity in vivo in rabbits

Current Therapeutic Research - Clinical and Experimental

Volumn 57, Issue 3, 1996, Pages 192-202

  Okada, Hitoshi ^a   Lundgren, Craig ^b   Brown, Steven L ^b   Vinogradsky, Boris ^a   Wülfroth, Petra ^c   Fujii, Satoshi ^a  

^a UNIVERSITY OF VERMONT COLLEGE OF MEDICINE   (United States)

^b WASHINGTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c MERZ PHARMACEUTICALS GMBH   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANTILIPEMIC AGENT; ETOFIBRATE; MESSENGER RNA; NICANARTINE; PLASMINOGEN ACTIVATOR INHIBITOR 1; TRANSFORMING GROWTH FACTOR BETA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; BIOSYNTHESIS; BLOOD LEVEL; BLOOD VESSEL INJURY; CELL CULTURE; CONTROLLED STUDY; ENDOTHELIUM CELL; GENE EXPRESSION; HEPATOMA CELL; HUMAN; HUMAN CELL; HYPERCHOLESTEROLEMIA; NONHUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; RABBIT; SMOOTH MUSCLE FIBER; UMBILICAL VEIN; VASCULAR ENDOTHELIUM; VASCULAR SMOOTH MUSCLE;

EID: 0030005850     PISSN: 0011393X     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0011-393X(96)80125-1     Document Type: Article

References (23)

1. Loskutoff DJ. Regulation of PAI-1 gene expression. Fibrinolysis. 1991;5:197-206.
2. Wieczorek I, Ludlam CA, Fox KAA. Tissue-type plasminogen activator and plasminogen activator inhibitor activities as predictors of adverse events in unstable angina. Am J Cardiol. 1994;74:424-429.
3. Ihnken K, Speiser W, Ruf W, et al. High PAI activity with correlation to triglyceride and HDL cholesterol values in patients with coronary artery disease with no difference in survivors of myocardial infarction. Ann Hematol. 1993;67:237-244.
4. Mykkanen L, Ronnemaa T, Marniemi J, et al. Insulin sensitivity is not an independent determinant of plasma plasminogen activator inhibitor-1 activity. Arterioscler Thromb. 1994;14:1264-1271.
5. Fujii S, Sawa H, Sobel BE. Inhibition of endothelial cell expression of plasminogen activator inhibitor type-1 by gemfibrozil. Thromb Haemost. 1993;70:642-647.
6. Avellone G, DiGarbo V, Cordova R, et al. Effect of gemfibrozil treatment on the fibrinolysis system in patients with hypertriglyceridemia. Curr Ther Res. 1992;52:338-348.
7. Avellone G, DiGarbo V, Cordova R, et al. Fibrinolytic effect of gemfibrozil versus placebo administration in response to venous occlusion. Fibrinolysis. 1993;7:416-421.
8. Herrera E, Lasuncion MA, Castro M, et al. Studies with etofibrate in the rat. Part I: Effects on glycerol, free fatty acid and triacylglycerol metabolism. Biochim Biophys Acta. 1988;963:42-52.
9. Paoletti R, Franceschini G, Sirtori CR. Influence of bezafibrate, fenofibrate, nicotinic acid and etofibrate on plasma high-density lipoprotein levels. Am J Cardiol. 1983;52:21B-27B.
10. Betz E, Quack G. Effect of etofibrate on the development and the regression of atheromas in a rabbit model of atherosclerosis. Vasa. 1990;19:157-160.
11. Wülfroth P. Nicanartine. Drugs Future. 1995;20:572-574.
12. Sawa H, Sobel BE, Fujii S. Potentiation by hypercholesterolemia of the induction of aortic intramural synthesis of plasminogen activator inhibitor type 1 by endothelial injury. Circ Res. 1993;73:671-680.
13. Jaffe EA, Nachman RL, Becker CG, Minick CR. Culture of human endothelial cells derived from umbilical veins. J Clin Invest. 1973;52:2745-2756.
14. Ross R. The smooth muscle cell II. Growth of smooth muscle in culture and formation of elastic fibers. J Cell Biol. 1971;50:172-186.
15. Sawa H, Sobel BE, Fujii S. Inhibition of type-1 plasminogen activator inhibitor production by antisense oligonucleotides in human vascular endothelial and smooth muscle cells. J Biol Chem. 1994;269:14149-14152.
16. Schneider DJ, Sobel BE. Augmentation of synthesis of plasminogen activator inhibitor type 1 by insulin and insulin-like growth factor type I: Implications for vascular disease in hyperinsulinemic states. Proc Natl Acad Sci USA. 1991;88:9959-9963.
17. Declerck PJ, Alessi MC, Verstreken M, et al. Measurement of plasminogen activator inhibitor 1 in biologic fluids with a murine monoclonal antibody-based enzyme-linked immunosorbent assay. Blood. 1988;71:220-225.
18. Chielewska J, Wiman B. Determination of tissue plasminogen activator and its "fast" inhibitor in plasma. Clin Chem. 1986;32:482-485.
19. Schneiderman J, Sawdey MS, Keeton MR, et al. Increased type 1 plasminogen activator inhibitor gene expression in atherosclerotic human arteries. Proc Natl Acad Sci USA. 1992;89:6998-7002.
20. Lupu F, Bergonzelli GE, Heim DA, et al. Localization and production of plasminogen activator inhibitor-1 in human healthy and atherosclerotic arteries. Arterioscler Thromb. 1993;13:1090-1100.
21. Stringer HAR, van Swieten P, Heijnen HFG, et al. Plasminogen activator inhibitor-1 released from activated platelets plays a key role in thrombolysis resistance. Studies with thrombi generated in the Chandler Loop. Arterioscler Thromb. 1994;14:1452-1458.
22. Latron Y, Chautan M, Anfosso F, et al. Stimulating effect of oxidized low density lipoproteins on plasminogen activator inhibitor-1 synthesis by endothelial cells. Arterioscler Thromb. 1991;11:1821-1829.
23. Kugiyama K, Sakamoto T, Misumi I, et al. Transferable lipids in oxidized low-density lipoprotein stimulate plasminogen activator inhibitor-1 and inhibit tissue-type plasminogen activator release from endothelial cells. Circ Res. 1993;73:335-343.